title: Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
abstract: OBJECTIVE
  Hepatic arterial infusion (HAI) chemotherapy has a number of limitations, including a low rate of complete response and frequent extrahepatic recurrence, in colorectal cancer patients with non-resectable hepatic metastases.
  
  
  METHODS
  Twenty-nine colorectal cancer patients with non-resectable hepatic metastases were consecutively enrolled for HAI alternating with systemic chemotherapy (HA + SC group). The protocol comprised six cycles of alternating HAI (5-FU + leucovorin for 14 days, and mitomycin C on the first day) and systemic chemotherapy (5-FU + leucovorin). Colorectal cancer patients with two or more hepatic metastases treated using hepatic resection and systemic chemotherapy (HR + SC group) were selected as a comparative group.
  
  
  RESULTS
  Within the HA + SC group, complete response was achieved in eight patients (28%), whereas 13 patients (45%) showed progressive disease. Six of the eight patients with complete response lived for more than 38 months. Extrahepatic recurrences were more frequent in the HR + SC group than the HA + SC group (47 vs 21%, P = 0.024). The two groups did not differ with respect to overall and hepatic progression-free survival (P = 0.947 and 0.444, respectively), displaying median +/- SE values of 38 +/- 7 and 20 +/- 3 months in the HA + SC group, and 39 +/- 9 and 33 +/- 14 months in the HR + SC group, respectively. One patient in each group experienced toxic hepatitis, and sclerosing cholangitis occurred in one patient of the HA + SC group. Other complications were mostly grade 1 or 2.
  
  
  CONCLUSIONS
  HAI alternating with systemic chemotherapy led to a promising response and hepatic progression-free survival, possibly reducing extrahepatic recurrence in colorectal cancer patients with non-resectable liver metastases.
authors.affiliation: Department of Surgery, University of Ulsan College of Medicine, 388-1 Poongnap-2-Dong, Songpa-Ku, Seoul 138-736, Korea. jckim@amc.seoul.kr
authors.forename: Jin C
authors.initials: JC
authors.lastname: Kim
authors.forename: Hee C
authors.initials: HC
authors.lastname: Kim
authors.forename: Kang H
authors.initials: KH
authors.lastname: Lee
authors.forename: Chang S
authors.initials: CS
authors.lastname: Yu
authors.forename: Tae W
authors.initials: TW
authors.lastname: Kim
authors.forename: Heung M
authors.initials: HM
authors.lastname: Chang
authors.forename: Min H
authors.initials: MH
authors.lastname: Ryu
authors.forename: Jong H
authors.initials: JH
authors.lastname: Kim
authors.forename: Hyun K
authors.initials: HK
authors.lastname: Ha
authors.forename: Moon G
authors.initials: MG
authors.lastname: Lee
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D002955:Leucovorin; D005472:Fluorouracil